UA80092C2 - Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition - Google Patents

Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition Download PDF

Info

Publication number: UA80092C2
Authority: UA; Ukraine
Prior art keywords: product according; filler; melt; granular product; gaboxadol
Prior art date: 2001-05-21

Application number

UA20031110120A

Other languages

English (en)

Ukrainian (uk)

Inventor

Michiel Onne Elema

Lene Andresen

Per Holm

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-21

Filing date

2002-05-17

Publication date

2007-08-27

2002-05-17 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2007-08-27 Publication of UA80092C2 publication Critical patent/UA80092C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 24
ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title claims abstract description 19
229950004346 gaboxadol Drugs 0.000 title claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 title claims 2
238000002360 preparation method Methods 0.000 title abstract description 8
150000003839 salts Chemical class 0.000 claims abstract description 12
239000007787 solid Substances 0.000 claims abstract description 10
239000002552 dosage form Substances 0.000 claims abstract description 9
238000002844 melting Methods 0.000 claims description 25
230000008018 melting Effects 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 19
239000011230 binding agent Substances 0.000 claims description 18
239000000945 filler Substances 0.000 claims description 18
229920001223 polyethylene glycol Polymers 0.000 claims description 12
239000000546 pharmaceutical excipient Substances 0.000 claims description 11
229920002261 Corn starch Polymers 0.000 claims description 9
239000008120 corn starch Substances 0.000 claims description 9
239000002202 Polyethylene glycol Substances 0.000 claims description 8
238000010438 heat treatment Methods 0.000 claims description 6
239000012943 hotmelt Substances 0.000 claims description 6
239000008118 PEG 6000 Substances 0.000 claims description 5
229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 5
238000012545 processing Methods 0.000 claims description 5
239000012458 free base Substances 0.000 claims description 4
239000000654 additive Substances 0.000 claims description 2
239000011248 coating agent Substances 0.000 claims description 2
238000000576 coating method Methods 0.000 claims description 2
239000000155 melt Substances 0.000 claims description 2
238000012876 topography Methods 0.000 claims 1
239000002253 acid Substances 0.000 abstract description 4
238000007909 melt granulation Methods 0.000 abstract 1
239000004480 active ingredient Substances 0.000 description 18
238000005469 granulation Methods 0.000 description 15
230000003179 granulation Effects 0.000 description 15
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000003979 granulating agent Substances 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
239000001506 calcium phosphate Substances 0.000 description 6
235000011010 calcium phosphates Nutrition 0.000 description 6
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
-1 for example Chemical class 0.000 description 5
229910052742 iron Inorganic materials 0.000 description 5
239000002245 particle Substances 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
229920000881 Modified starch Polymers 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000005260 corrosion Methods 0.000 description 4
230000007797 corrosion Effects 0.000 description 4
239000008187 granular material Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
238000002156 mixing Methods 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
238000003825 pressing Methods 0.000 description 3
229940032147 starch Drugs 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000013543 active substance Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011132 calcium sulphate Nutrition 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
238000011161 development Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
235000019700 dicalcium phosphate Nutrition 0.000 description 2
238000007907 direct compression Methods 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
235000019426 modified starch Nutrition 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
239000004135 Bone phosphate Substances 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
150000008043 acidic salts Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229910052814 silicon oxide Inorganic materials 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Anesthesiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

UA20031110120A 2001-05-21 2002-05-17 Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition UA80092C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200100817		2001-05-21
PCT/DK2002/000332 WO2002094225A1 (en)	2001-05-21	2002-05-17	Granular preparations of gaboxadol

Publications (1)

Publication Number	Publication Date
UA80092C2 true UA80092C2 (en)	2007-08-27

Family

ID=8160520

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20031110120A UA80092C2 (en)	2001-05-21	2002-05-17	Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition

Country Status (26)

Country	Link
US (1)	US20040157876A1 (pl)
EP (1)	EP1389091A1 (pl)
JP (1)	JP2004530695A (pl)
KR (1)	KR20030097890A (pl)
CN (1)	CN1511026A (pl)
AR (1)	AR033896A1 (pl)
AU (1)	AU2002338855B2 (pl)
BG (1)	BG108441A (pl)
BR (1)	BR0209834A (pl)
CA (1)	CA2447603A1 (pl)
CZ (1)	CZ20033269A3 (pl)
EA (2)	EA009731B1 (pl)
HR (1)	HRP20030950A2 (pl)
HU (1)	HUP0400051A2 (pl)
IL (1)	IL158733A0 (pl)
IS (1)	IS7020A (pl)
ME (1)	MEP6308A (pl)
MX (1)	MXPA03010596A (pl)
NO (1)	NO20035146D0 (pl)
NZ (1)	NZ547636A (pl)
PL (1)	PL366541A1 (pl)
SK (1)	SK15542003A3 (pl)
UA (1)	UA80092C2 (pl)
WO (1)	WO2002094225A1 (pl)
YU (1)	YU92103A (pl)
ZA (1)	ZA200308594B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1220658A1 (en) *	1999-09-28	2002-07-10	H. Lundbeck A/S	Melt granulated composition and modified release dosage form prepared from said composition
DK1641456T3 (da)	2003-06-25	2010-06-21	Lundbeck & Co As H	Gaboxadol til behandling af depression og andre affektive lidelser
TW200528098A (en) *	2003-12-18	2005-09-01	Lundbeck & Co As H	Treatment of insomnia in human patients
GB0402118D0 (en)	2004-01-30	2004-03-03	Merck Sharp & Dohme	Polymorphic forms of a GABAA agonist
WO2006083682A2 (en)	2005-01-28	2006-08-10	H.Lundbeck A/S	Polymorphic forms of a gabaa agonist
US20080262029A1 (en) *	2005-04-29	2008-10-23	H. Lundbeck A/S	Acid and Base Salt Forms of Gaboxadol
CN103054868B (zh) *	2008-05-30	2016-08-31	赛科基因股份有限公司	用于神经和精神障碍的治疗
CN102137667A (zh) *	2008-09-01	2011-07-27	H.隆德贝克有限公司	包含加波沙朵和patl或oat抑制剂的药物组合物
WO2013090452A1 (en)	2011-12-12	2013-06-20	Orbis Biosciences, Inc.	Sustained release particle formulations
IL256912B2 (en)	2015-07-17	2024-01-01	Ovid Therapeutics Inc	Methods of treating developmental disorders with gaboxadol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4315934A (en) *	1979-09-24	1982-02-16	Sandoz Ltd.	Organic compounds
DE19525598C2 (de) *	1995-07-13	1997-09-25	Max Planck Gesellschaft	Schlafmittel
US6649186B1 (en) *	1996-09-20	2003-11-18	Ethypharm	Effervescent granules and methods for their preparation
EP1220658A1 (en) *	1999-09-28	2002-07-10	H. Lundbeck A/S	Melt granulated composition and modified release dosage form prepared from said composition
US6375982B1 (en) *	2000-07-05	2002-04-23	Capricorn Pharma, Inc.	Rapid-melt semi-solid compositions, methods of making same and method of using same

2002
- 2002-05-17 CN CNA028104587A patent/CN1511026A/zh active Pending
- 2002-05-17 EA EA200301282A patent/EA009731B1/ru not_active IP Right Cessation
- 2002-05-17 JP JP2002590944A patent/JP2004530695A/ja active Pending
- 2002-05-17 AU AU2002338855A patent/AU2002338855B2/en not_active Ceased
- 2002-05-17 CA CA002447603A patent/CA2447603A1/en not_active Abandoned
- 2002-05-17 PL PL02366541A patent/PL366541A1/pl not_active Application Discontinuation
- 2002-05-17 BR BR0209834-2A patent/BR0209834A/pt not_active IP Right Cessation
- 2002-05-17 EP EP02742834A patent/EP1389091A1/en not_active Ceased
- 2002-05-17 MX MXPA03010596A patent/MXPA03010596A/es not_active Application Discontinuation
- 2002-05-17 UA UA20031110120A patent/UA80092C2/uk unknown
- 2002-05-17 SK SK1554-2003A patent/SK15542003A3/sk not_active Application Discontinuation
- 2002-05-17 HU HU0400051A patent/HUP0400051A2/hu unknown
- 2002-05-17 HR HR20030950A patent/HRP20030950A2/hr not_active Application Discontinuation
- 2002-05-17 CZ CZ20033269A patent/CZ20033269A3/cs unknown
- 2002-05-17 IL IL15873302A patent/IL158733A0/xx unknown
- 2002-05-17 WO PCT/DK2002/000332 patent/WO2002094225A1/en not_active Ceased
- 2002-05-17 AR ARP020101839A patent/AR033896A1/es unknown
- 2002-05-17 EA EA200700703A patent/EA200700703A1/ru unknown
- 2002-05-17 NZ NZ547636A patent/NZ547636A/en unknown
- 2002-05-17 ME MEP-63/08A patent/MEP6308A/xx unknown
- 2002-05-17 KR KR10-2003-7015136A patent/KR20030097890A/ko not_active Ceased
- 2002-05-17 YU YU92103A patent/YU92103A/sh unknown
- 2002-05-17 US US10/478,983 patent/US20040157876A1/en not_active Abandoned
2003
- 2003-11-04 ZA ZA200308594A patent/ZA200308594B/en unknown
- 2003-11-10 IS IS7020A patent/IS7020A/is unknown
- 2003-11-19 NO NO20035146A patent/NO20035146D0/no not_active Application Discontinuation
- 2003-12-12 BG BG108441A patent/BG108441A/xx unknown

Also Published As

Publication number	Publication date
WO2002094225A1 (en)	2002-11-28
CA2447603A1 (en)	2002-11-28
AU2002338855B2 (en)	2007-08-16
HUP0400051A2 (hu)	2004-04-28
EA200700703A1 (ru)	2007-08-31
ZA200308594B (en)	2004-11-04
MEP6308A (xx)	2010-02-10
AR033896A1 (es)	2004-01-07
BR0209834A (pt)	2004-06-15
BG108441A (en)	2005-02-28
CZ20033269A3 (en)	2004-03-17
JP2004530695A (ja)	2004-10-07
NO20035146L (no)	2003-11-19
EA200301282A1 (ru)	2004-04-29
IL158733A0 (en)	2004-05-12
HRP20030950A2 (en)	2005-08-31
MXPA03010596A (es)	2004-03-09
KR20030097890A (ko)	2003-12-31
IS7020A (is)	2003-11-10
EA009731B1 (ru)	2008-02-28
PL366541A1 (pl)	2005-02-07
YU92103A (sh)	2006-05-25
EP1389091A1 (en)	2004-02-18
SK15542003A3 (sk)	2004-05-04
US20040157876A1 (en)	2004-08-12
NZ547636A (en)	2008-03-28
CN1511026A (zh)	2004-07-07
NO20035146D0 (no)	2003-11-19

Publication	Publication Date	Title
AU750978B2 (en)	2002-08-01	Polymorphic crystalline forms of celecoxib
AU2006226293B2 (en)	2011-04-07	Solubilized ibuprofen
CZ20013376A3 (cs)	2002-02-13	Způsob výroby nehygroskopických solí L(-)-karnitinu
JP2002509886A (ja)	2002-04-02	メロキシカムの経口投与用新規ガレヌス調製物
JP4875001B2 (ja)	2012-02-15	アリピプラゾールの湿式造粒医薬組成物
UA80092C2 (en)	2007-08-27	Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition
CZ282271B6 (cs)	1997-06-11	Způsob přípravy farmaceutického prostředku
JP2001518503A (ja)	2001-10-16	５−（２−エチル−２ｈ−テトラゾール−５−イル）−１−メチル−１，２，３，６−テトラヒドロピリジンの粒状調合物
JP2003531153A (ja)	2003-10-21	シタロプラムを含有する薬学的調合物
AU2002338855A1 (en)	2003-05-08	Granular preparations of gaboxadol
WO2012019633A1 (en)	2012-02-16	Pharmaceutical granulate comprising imatinib mesylate
JP2003518486A (ja)	2003-06-10	トラマドール・ハイドロクロライドを含む放出の調整された医薬組成物およびその調製方法
RU2183119C1 (ru)	2002-06-10	Фармацевтическая композиция, обладающая спазмолитической активностью, способ ее получения
JP2841857B2 (ja)	1998-12-24	長期間安定な経口用医薬製剤
EP1800667A1 (en)	2007-06-27	Rapidly solubilizing ibuprofen granulate
JP3232687B2 (ja)	2001-11-26	イミダプリル含有製剤
Gawshinde	2024	Formulation, development and evaluation of paracetamol tablet by moisture activated dry granulation (MADG) process
JPH09110698A (ja)	1997-04-28	経口用医薬組成物の製造法
PL236614B1 (pl)	2021-02-08	Kompozycja farmaceutyczna zawierająca febuksostat oraz sposób jej wytwarzania
SK285964B6 (sk)	2007-12-06	Liečivý prípravok obsahujúci fexofenadín hydrochlorid a spôsob jeho prípravy